$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

$jazz Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000123252415000140 Filed on August 05, 2015

Income Statement

Concept	2015 Q2	2014 Q2
Revenue	$333.7M	$291.2M
YoY Change	14.6%	39.84%
Cost Of Revenue	$21.80M	$30.70M
YoY Change	-28.99%	22.8%
Gross Profit	$310.3M	$258.4M
YoY Change	20.08%	42.35%
Gross Profit Margin	92.97%	88.73%
Selling, General & Admin	$107.1M	$100.6M
YoY Change	6.54%	29.74%
% of Gross Profit	34.53%	38.91%
Research & Development	$27.83M	$20.09M
YoY Change	38.54%	117.19%
% of Gross Profit	8.97%	7.77%
Depreciation & Amortization	$26.00M	$34.70M
YoY Change	-25.07%	73.5%
% of Gross Profit	8.38%	13.43%
Operating Expenses	$180.4M	$216.9M
YoY Change	-16.82%	65.37%
Operating Profit	$153.3M	$74.29M
YoY Change	106.35%	-3.6%
Interest Expense	-$15.81M	-$11.43M
YoY Change	38.35%	60.03%
% of Operating Profit	-10.31%	-15.38%
Other Income/Expense, Net	-$1.914M
YoY Change
Pretax Income	$118.8M	$62.94M
YoY Change	88.7%	-4.34%
Income Tax	$30.65M	$19.35M
% Of Pretax Income	25.81%	30.75%
Net Earnings	$88.11M	$43.66M
YoY Change	101.82%	3.49%
Net Earnings / Revenue	26.4%	14.99%
Basic Earnings Per Share	$1.44	$0.73
Diluted Earnings Per Share	$1.40	$0.70
COMMON SHARES
Basic Shares Outstanding	61.19M shares	59.52M shares
Diluted Shares Outstanding	63.09M shares	62.38M shares

Balance Sheet

Concept	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$921.6M	$268.3M
YoY Change	243.5%	-46.8%
Cash & Equivalents	$921.6M	$268.3M
Short-Term Investments	$922.0M	$268.0M
Other Short-Term Assets	$21.99M	$18.47M
YoY Change	19.04%	-6.33%
Inventory	$30.78M	$33.10M
Prepaid Expenses	$26.25M	$28.45M
Receivables	$193.6M	$160.8M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.245B	$544.9M
YoY Change	128.46%	-25.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$80.43M	$38.46M
YoY Change	109.11%	257.19%
Goodwill	$664.0M	$760.3M
YoY Change	-12.67%	73.19%
Intangibles	$1.283B	$1.680B
YoY Change	-23.63%	104.14%
Long-Term Investments
YoY Change
Other Assets	$22.50M	$11.14M
YoY Change	102.05%	102.38%
Total Long-Term Assets	$2.148B	$2.611B
YoY Change	-17.71%	92.02%
TOTAL ASSETS
Total Short-Term Assets	$1.245B	$544.9M
Total Long-Term Assets	$2.148B	$2.611B
Total Assets	$3.393B	$3.156B
YoY Change	7.53%	50.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$26.41M	$32.56M
YoY Change	-18.88%	59.84%
Accrued Expenses	$146.1M	$142.8M
YoY Change	2.25%	47.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$28.48M	$9.473M
YoY Change	200.62%	70.01%
Total Short-Term Liabilities	$225.2M	$197.8M
YoY Change	13.85%	7.28%
LONG-TERM LIABILITIES
Long-Term Debt	$1.338B	$1.187B
YoY Change	12.72%	117.1%
Other Long-Term Liabilities	$52.66M	$29.18M
YoY Change	80.51%	118.87%
Total Long-Term Liabilities	$1.391B	$1.216B
YoY Change	14.35%	117.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$225.2M	$197.8M
Total Long-Term Liabilities	$1.391B	$1.216B
Total Liabilities	$1.616B	$1.414B
YoY Change	14.28%	89.94%
SHAREHOLDERS EQUITY
Retained Earnings	$181.8M	-$53.95M
YoY Change	-437.06%	84.34%
Common Stock	$1.512B	$1.273B
YoY Change	18.79%	7.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.447B	$1.280B
YoY Change
Total Liabilities & Shareholders Equity	$3.393B	$3.156B
YoY Change	7.53%	50.71%

Cashflow Statement

Concept	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	$88.11M	$43.66M
YoY Change	101.82%	3.49%
Depreciation, Depletion And Amortization	$26.00M	$34.70M
YoY Change	-25.07%	73.5%
Cash From Operating Activities	$140.5M	$74.90M
YoY Change	87.58%	760.92%
INVESTING ACTIVITIES
Capital Expenditures	-$13.00M	-$13.20M
YoY Change	-1.52%	266.67%
Acquisitions
YoY Change
Other Investing Activities	$1.000M	$0.00
YoY Change
Cash From Investing Activities	-$12.00M	-$13.10M
YoY Change	-8.4%	263.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.300M	-39.50M
YoY Change	-118.48%	-183.16%
NET CHANGE
Cash From Operating Activities	140.5M	74.90M
Cash From Investing Activities	-12.00M	-13.10M
Cash From Financing Activities	7.300M	-39.50M
Net Change In Cash	135.8M	22.30M
YoY Change	508.97%	-57.6%
FREE CASH FLOW
Cash From Operating Activities	$140.5M	$74.90M
Capital Expenditures	-$13.00M	-$13.20M
Free Cash Flow	$153.5M	$88.10M
YoY Change	74.23%	616.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001232524
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61339267	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Jazz Pharmaceuticals plc
	dei	Trading Symbol TradingSymbol	JAZZ
CY2014Q4	jazz	Accrued Construction In Progress AccruedConstructionInProgress	4931000	USD
CY2015Q2	jazz	Accrued Construction In Progress AccruedConstructionInProgress	3387000	USD
CY2014Q4	jazz	Accrued Interest AccruedInterest	10327000	USD
CY2015Q2	jazz	Accrued Interest AccruedInterest	4656000	USD
CY2014Q4	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	51899000	USD
CY2015Q2	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	61230000	USD
CY2014Q4	jazz	Capital Redemption Reserve CapitalRedemptionReserve	471000	USD
CY2015Q2	jazz	Capital Redemption Reserve CapitalRedemptionReserve	471000	USD
CY2014Q4	jazz	Computer Equipment Gross ComputerEquipmentGross	7670000	USD
CY2015Q2	jazz	Computer Equipment Gross ComputerEquipmentGross	10332000	USD
CY2014Q2	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	30692000	USD
	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	61616000	USD
CY2015Q2	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	21813000	USD
	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	50111000	USD
CY2014Q4	jazz	Entity Wide Accounts Receivable Major Customer Percentage EntityWideAccountsReceivableMajorCustomerPercentage	0.86
CY2015Q2	jazz	Entity Wide Accounts Receivable Major Customer Percentage EntityWideAccountsReceivableMajorCustomerPercentage	0.88
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	9702000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3302000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1849000	USD
	jazz	Fair Value Inventory Step Up Adjustment FairValueInventoryStepUpAdjustment	10477000	USD
	jazz	Fair Value Inventory Step Up Adjustment FairValueInventoryStepUpAdjustment	0	USD
CY2014Q2	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	0	USD
	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	0	USD
CY2015Q2	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	-16815000	USD
	jazz	Gain Losson Extinguishmentand Modificationof Debt GainLossonExtinguishmentandModificationofDebt	-16815000	USD
	jazz	Increase Decreasein Contingent Consideration IncreaseDecreaseinContingentConsideration	-14900000	USD
	jazz	Increase Decreasein Contingent Consideration IncreaseDecreaseinContingentConsideration	0	USD
CY2014Q4	jazz	Landand Buildings Gross LandandBuildingsGross	1547000	USD
CY2015Q2	jazz	Landand Buildings Gross LandandBuildingsGross	1693000	USD
	jazz	Loss Contingency Radiopharmaceutical Products Number LossContingencyRadiopharmaceuticalProductsNumber	2	product
CY2014Q4	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2015Q2	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2014Q4	jazz	Number Of Customers With Significant Accounts Receivable Balance NumberOfCustomersWithSignificantAccountsReceivableBalance	5	Customer
CY2015Q2	jazz	Number Of Customers With Significant Accounts Receivable Balance NumberOfCustomersWithSignificantAccountsReceivableBalance	5	Customer
	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	127000000	USD
	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	0	USD
	jazz	Proceeds From Employee Stock Purchases And Exercise Of Stock Options And Warrants ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptionsAndWarrants	31642000	USD
	jazz	Proceeds From Employee Stock Purchases And Exercise Of Stock Options And Warrants ProceedsFromEmployeeStockPurchasesAndExerciseOfStockOptionsAndWarrants	26730000	USD
	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	1925000	USD
	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	610000	USD
CY2014Q2	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	2130000	USD
	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	4063000	USD
CY2015Q2	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	1641000	USD
	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	3909000	USD
CY2014Q4	jazz	Sales Return Reserve SalesReturnReserve	14039000	USD
CY2015Q2	jazz	Sales Return Reserve SalesReturnReserve	8650000	USD
	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	31642000	USD
	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	26730000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	25126000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	26409000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	186371000	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	193647000	USD
CY2014Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	46143000	USD
CY2015Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	28062000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	164091000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	146053000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3295000	USD
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5622000	USD
CY2014Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7964000	USD
CY2015Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	10293000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15192000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19147000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-122097000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-248042000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1458005000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1512450000	USD
	us-gaap	Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation	10551000	USD
	us-gaap	Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation	16679000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32476000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	44394000	USD
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	792000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18552000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32367000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23300000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44119000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	13136000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	22665000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	16390000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	31055000	USD
CY2014Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	32795000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	63977000	USD
CY2015Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	23668000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	48345000	USD
CY2014Q4	us-gaap	Assets Assets	3338955000	USD
CY2015Q2	us-gaap	Assets Assets	3393274000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	1015845000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	1244910000	USD
CY2014Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	32833000	USD
CY2015Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	684042000	USD
CY2015Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	921643000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	684042000	USD
CY2015Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	921643000	USD
CY2014Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	10634000	USD
CY2015Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	12839000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	636504000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	268255000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	684042000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	921643000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-368249000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	237601000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	32713000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45198000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	118656000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	32869000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-347000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1059000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-9000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	32366000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-46257000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	118657000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	32860000	USD
CY2014Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	37145000	USD
CY2015Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	57876000	USD
CY2015Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1486496000	USD
CY2014Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	33174000	USD
CY2015Q2	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	25188000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-18598000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-16873000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1138000	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1330000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4499000	USD
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3930000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	48440000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	50604000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	75494000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	73280000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	9430000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	9438000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	375054000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	326707000	USD
	us-gaap	Depreciation Depreciation	3169000	USD
	us-gaap	Depreciation Depreciation	4595000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.60
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.70
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.40
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.52
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	233000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-9758000	USD
CY2014Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.307
CY2015Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.258
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.283
CY2014Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	5416000	USD
CY2015Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	6910000	USD
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	13064000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	792000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	792000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	265845000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	287695000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	655952000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	47863000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	88477000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	88698000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	91548000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	91548000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1466532000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1351781000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1200687000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1064086000	USD
CY2014Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2220000	USD
CY2015Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	2350000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-46000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-16815000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	702713000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	664015000	USD
	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-38698000	USD
CY2014Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	32806000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	32806000	USD
CY2015Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	62936000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13676000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	118760000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	221519000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19350000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36377000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30647000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62706000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-31555000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2129000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21889000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8479000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	5454000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	6497000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-821000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	13271000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-936000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13676000	USD
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	566000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-18135000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-557000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-382000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3365000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	6658000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	8461000	USD
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2293000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1900000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2030000	shares
CY2014Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1703280000	USD
CY2015Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1570650000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1437435000	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1282955000	USD
CY2014Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-11429000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-21505000	USD
CY2015Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-15812000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-32057000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	16597000	USD
CY2015Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12943000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	30037000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	30781000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3570000	USD
CY2015Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4079000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9870000	USD
CY2015Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	13759000	USD
CY2014Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7931000	USD
CY2015Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	8735000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3338955000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3393274000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	216801000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	225164000	USD
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	1342428000	USD
CY2015Q2	us-gaap	Long Term Debt LongTermDebt	1366464000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	9428000	USD
CY2015Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	28478000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	1255450000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	79791000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	61169000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	42547000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	37855000	USD
CY2015Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	9684000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1333000000	USD
CY2015Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1337986000	USD
CY2014Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	6408000	USD
CY2015Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	5750000	USD
CY2014Q4	us-gaap	Minority Interest MinorityInterest	64000	USD
CY2015Q2	us-gaap	Minority Interest MinorityInterest	55000	USD
	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	136640000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	458207000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3962000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-970336000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6271000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	143647000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	237126000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	43659000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-48991000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	88114000	USD
	us-gaap	Net Income Loss NetIncomeLoss	158814000	USD
CY2014Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-73000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1062000	USD
CY2015Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000	USD
	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	136578000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	216939000	USD
	us-gaap	Operating Expenses OperatingExpenses	530517000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	180446000	USD
	us-gaap	Operating Expenses OperatingExpenses	372990000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	74291000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	7632000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	153301000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	270060000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	117600000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	7192000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	7803000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	12267000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	11434000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	73273000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	5631000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	25493000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	24153000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	21322000	USD
CY2015Q2	us-gaap	Other Assets Current OtherAssetsCurrent	21985000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15931000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	22498000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3796000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-125953000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11220000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3796000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	30544000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-125953000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-11220000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3796000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	30544000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-125953000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	38393000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	52664000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2907000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-7938000	USD
CY2014Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	74000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	197000	USD
CY2015Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	-1914000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	331000	USD
	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	35100000	USD
	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	23487000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	11690000	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	2494000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	10551000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	16679000	USD
	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	136640000	USD
	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	828676000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	14660000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	27432000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12800000	USD
CY2015Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	26250000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	33703000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	636355000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	901003000	USD
CY2014Q2	us-gaap	Profit Loss ProfitLoss	43586000	USD
	us-gaap	Profit Loss ProfitLoss	-50053000	USD
CY2015Q2	us-gaap	Profit Loss ProfitLoss	88113000	USD
	us-gaap	Profit Loss ProfitLoss	158813000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	73555000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	99575000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58363000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80428000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	4804000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	895402000	USD
CY2014Q2	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	127000000	USD
CY2015Q2	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20090000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38199000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27833000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55014000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	34704000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	181828000	USD
CY2014Q2	us-gaap	Revenues Revenues	291230000	USD
	us-gaap	Revenues Revenues	538149000	USD
CY2015Q2	us-gaap	Revenues Revenues	333747000	USD
	us-gaap	Revenues Revenues	643050000	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	289100000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	534086000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	332106000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	639141000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	100556000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	206919000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	107132000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	219520000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	32367000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	44119000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	23487000	USD
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	11690000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	1371144000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	1446768000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1295534000	USD
CY2014Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1280087000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1371208000	USD
CY2015Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1446823000	USD
CY2014Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	7588000	USD
CY2015Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	13456000	USD
CY2015Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	36400000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62378000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59025000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63090000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63028000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59519000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59025000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61190000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60998000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities and issuers of investments to the extent recorded on the balance sheet.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the United States, and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> customers accounted for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">88%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliates, or Express Scripts, which accounted for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">70%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable and IDIS Limited, or IDIS, which accounted for </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable.  As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> customers accounted for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">86%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, including Express Scripts, which accounted for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">66%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, and IDIS, which accounted for </font><font style="font-family:inherit;font-size:10pt;">11%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We depend on single source suppliers and manufacturers for each of our products, product candidates and their active pharmaceutical ingredients.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001232524-15-000140-index-headers.html	Edgar Link	pending
0001232524-15-000140-index.html	Edgar Link	pending
0001232524-15-000140.txt	Edgar Link	pending
0001232524-15-000140-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
jazz-20150630.xml	Edgar Link	completed
jazz-20150630.xsd	Edgar Link	pending
jazz-20150630_cal.xml	Edgar Link	unprocessable
jazz-20150630_def.xml	Edgar Link	unprocessable
jazz-20150630_lab.xml	Edgar Link	unprocessable
jazz-20150630_pre.xml	Edgar Link	unprocessable
jazz2015q2doc.htm	Edgar Link	pending
jazzq22015ex102.htm	Edgar Link	pending
jazzq22015ex103.htm	Edgar Link	pending
jazzq22015ex311.htm	Edgar Link	pending
jazzq22015ex312.htm	Edgar Link	pending
jazzq22015ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

2015 Q2 Form 10-Q Financial Statement

#000123252415000140 Filed on August 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ Jazz Pharmaceuticals PLC Stock $jazz

2015 Q2 Form 10-Q Financial Statement

#000123252415000140 Filed on August 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz